Login to Your Account



Clinic Roundup


Thursday, March 24, 2011
• Rexahn Pharmaceuticals Inc., of Rockville, Md., enrolled 100 of a total 300 patients required for a Phase IIb trial of Serdaxin in major depressive disorder. Enrollment will be completed in the first half of 2011, with preliminary results expected in late 2011. The trial will measure changes from baseline on the Montgomery Asberg Depression Rating Scale.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription